Between April 1985 and March 1994 (9 years), 229 346 babies were born in Niigata prefecture, and 201 888 (88.0%) underwent mass screening (MS) for neuroblastoma at 6 months of age.
To date, 29 infants have been screen-detected as having neuroblastoma (1 : 7908).
All screen-detected patients survived after removal of the primary tumor.
In the same birth cohort, 17 additional children were clinically diagnosed as having neuroblastoma.
The cumulative incidence rate of neuroblastoma at 5 years of age was 10.5 per 100 000 live births in the 5-year birth cohort before MS was introduced, and 18.6 per 100000 in the first 5-year birth cohort after MS was introduced.
These values were not statistically different.
The birth cohort incidence rate increased significantly to 22.2 per 100000 (p<5% compared with before MS) after the method of MS was changed to high-power liquid chromatography (HPLC), even though this latest birth cohort has not been followed for 5 years.
The population-based mortality rate from neuroblastoma was 5.9 per 100000 in the 5-year birth cohort before MS, and 4.5 per 100 000 after MS in the first 5-year birth cohort, using the vanillymandelic acid (VMA) spot test.
These values were not statistically significant.
In contrast, no death was observed in the next 4-year birth cohort after MS using HPLC ; however, this birth chohort has not yet been followed for 5 years.
Mots-clés Pascal : Système nerveux pathologie, Dépistage, Enfant, Homme, Neuroblastome, Tumeur maligne, Système nerveux sympathique pathologie, Japon, Asie, Etude cohorte
Mots-clés Pascal anglais : Nervous system diseases, Medical screening, Child, Human, Neuroblastoma, Malignant tumor, Autonomic neuropathy, Japan, Asia, Cohort study
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0000622
Code Inist : 002B17E. Création : 01/03/1996.